[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592843":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":56,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":11,"overallStatus":23,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ICD patients","EXPERIMENTAL",null,[13],"Biological: REGEND001 Autologous Basal Layer Stem Cell Suspension",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","REGEND001 Autologous Basal Layer Stem Cell Suspension","REGEND001 Autologous Basal Layer Stem Cell Suspension is an innovative cell therapy product designed for chronic structural lung diseases, such as bronchiectasis. This treatment involves harvesting regenerative stem cells (expressing KRT5\u002FP63 markers) from the patient's own bronchial basal layer via fiberoptic bronchoscopy. After isolation, purification, and ex vivo expansion, the cells are administered as a suspension through bronchoscopic infusion into damaged lung segments.",[9],[21,41],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine","RECRUITING","Qionghai","Hainan","571437","China","CN",{"type":30,"coordinates":31},"Point",[32,33],110.46417,19.2425,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Wen Su","CONTACT","0898-62621907","sw11831@rjh.com",{"facility":42,"status":23,"city":43,"state":44,"zip":45,"country":27,"countryCode":28,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200025",{"type":30,"coordinates":47},[48,49],121.45806,31.22222,{"lat":49,"lon":48},[52],{"name":53,"role":38,"phone":54,"phoneExt":11,"email":55},"Jiayang Yan, Ph.D","86-21-64370045","yjy19960816@163.com",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Jieming QU","Professor","100592843","phase-1-regend001-autologous-basal-layer-stem-cell-transplantation-for-interstitial-lung-disease-ild-a-translational-application-study-100592843",false,"NCT06998706","REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study","Inclusion Criteria:\n\n1. Age 40-75 years.\n2. Confirmed diagnosis of ILD (e.g., IPF, connective tissue disease-associated ILD).\n3. DLCO ≥30% and \\\u003C80% predicted.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or plans for pregnancy within 1 year.\n2. Active malignancy or history of malignancy.\n3. Positive serology for HIV, HBV, HCV, or syphilis.","ALL","40 Years","75 Years",{"count":70,"type":71},10,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harvesting the patient's own stem cells (expressing KRT5\u002FP63 markers), expanding them ex vivo, and administering them via bronchoscopic infusion to regenerate damaged lung tissue.",[77],"Interstitial Lung Disease (ILD)","2026-07-27",{"date":80,"type":81},"2026-07-28","ACTUAL",{"date":83,"type":81},"2025-06-19",{"date":85,"type":71},"2029-06-30",{"name":5,"class":6},2]